OncoGenex Adds David V. Smith to the Board of Directors
OncoGenex Pharmaceuticals, Inc. announced that the Company has appointed Mr. David V. Smith to its board of directors. Mr. Smith brings to the board substantial financial expertise in financial controls, analytics and process. Having served in executive financial positions for multi-billion dollar life sciences companies, Mr. Smith also adds deep experience in the design and implementation of strategic growth plans, including acquisitions. In his role on the board, Mr. Smith joins the audit committee and nomination and governance committee.
David V. Smith is the executive vice president and chief financial officer of Thoratec Corporation. Prior to joining Thoratec, David held various financial management positions with Chiron Corporation over a seven year period, including as vice president and chief financial officer. He previously served as the vice president, finance and chief financial officer of Anergen, Inc. Prior to joining Anergen, David held various financial management positions with Genentech, Inc. over a nine year period, in both the United States and Europe. David earned a bachelor of arts degree in economics and history from Willamette University and a master of business administration in finance from Golden Gate University. Previously, David was a member of the board of directors and chair of the audit committee of Perlegen Sciences, Inc.
Other news from the department people
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
